miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1

References

• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Shaji KK, Natalie SC, Melissa A, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Cancer Network. 2018;16(1):11–20.
   PubMed Web of Science ®Google Scholar
• Gourzones-Dmitriev C, Kassambara A, Sahota S, et al. DNA repair pathways in human multiple myeloma. Cell Cycle. 2013;12(17):2760–2773.
   PubMed Web of Science ®Google Scholar
• West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 2003;4:435.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, J-M H, M-T H, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165.
   PubMed Web of Science ®Google Scholar
• Paola N, Li R, Kathy G, et al. Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118(24):6368–6379.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gkotzamanidou M, Pal J, et al. Elevated APE1 mediates dysregulation of homologous recombination in myeloma: mechanisms and translational significance. Blood. 2014;124(21):2074.
   Web of Science ®Google Scholar
• Duo J, Wang G, Han X, et al. APE1 gene silencing promotes the sensitivity of osteosarcoma U2-OS cells to bortezomib. Zhongguo Zhong Liu Lin Chuang. 2012;39:429–432.
   Google Scholar
• Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer. 2012;118(4):878–887.
   PubMed Web of Science ®Google Scholar
• Vislovukh A, Vargas TR, Polesskaya A, et al. Role of 3ʹ-untranslated region translational control in cancer development, diagnostics and treatment. World J Biol Chem. 2014;5(1):40–57.
   PubMedGoogle Scholar
• Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer J Inter Du Cancer. 2010;126(1):2–10.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of 1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–588.
   PubMed Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48(3):589–601.
   PubMed Web of Science ®Google Scholar
• Marta L, Marta B, Luca A, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114(25):20–26.
   PubMed Web of Science ®Google Scholar
• Cosco D, Cilurzo F, Maiuolo J, et al. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep. 2015;5:17579.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo Y, Qi J, et al. Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells. Pathol Oncol Res Por. 2015;22(3):531–539.
   PubMed Web of Science ®Google Scholar
• Morelli E, Leone E, Cantafio MEG, et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29(11):2173–2183.
   PubMed Web of Science ®Google Scholar
• Neri P, Gratton K, Ren L, et al. miRNA expression in multiple myeloma as predictive model of response to bortezomib. Blood. 2009;114(22):4918.
   Google Scholar
• Chi J, Ballabio E, Chen X-H, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6(1):23.
   PubMedGoogle Scholar
• Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009;16(6):533–546.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Geng L, Talmon G, et al. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem. 2015;290(10):6215–6225.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu L, Sun Y, et al. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget. 2016;7(18):26516–26534.
   PubMedGoogle Scholar
• Shen Q, Yao Q, Sun J, et al. Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Lett. 2014;588(1):184–191.
   PubMed Web of Science ®Google Scholar
• Padmanabhan R, Chen KG, Gillet J-P, et al. Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells. 2012;30(10):2175–2187.
   PubMed Web of Science ®Google Scholar
• Wilson DM, Anton S. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci. 2010;67(21):3621–3631.
   PubMed Web of Science ®Google Scholar
• Wang D, Xiang DB, Yang XQ, et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009;66(3):298–304.
   PubMed Web of Science ®Google Scholar
• Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther. 2004;3(3):679–686.
   PubMedGoogle Scholar
• Xie J, Zhang L, Li M, et al. Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma. BMC Cancer. 2014;14:11.
   PubMed Web of Science ®Google Scholar